Le possibilità di formazione all'estero

La Scuola offre ai Medici in formazione importanti opportunità di collaborazione e formazione all'estero per integrare il proprio percorso. La Scuola vanta strette collaborazioni con prestigiosi centri internazionali per la diagnosi e cura della sindrome di Sjögren (Queen Mary University, Londra, UK; University of Athens, Atene, Grecia), delle vasculiti sistemiche (CIMA Hospital, Barcellona, Spagna), e delle artriti infiammatorie (University of Leeds, Leeds, UK).

Studi internazionali attualmente in corso presso la Clinica

1. New Clinical End-points in patients with primary Sjögren's Syndrome (pSS): an Interventional Trial based on stratifYing patients (APHP190131) - studio interventistico no profit – promotore l’Hôpital Saint-Louis, 1, Paris, France
2. A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Participants with New-onset or Relapsing Giant Cell Arteritis (CNTO1959GCA2001) - studio interventistico profit – Sponsor J&J
3. A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with active Sjögren’s syndrome (CVAY736A2302) – studio interventistico profit – Sponsor Novartis
4. A randomized, double-blind, parallel group, placebo-controlled, multicenter phase 3 trial to evaluate the efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in participants with active lupus nephritis (CVAY736K12301) – studio interventistico profit – Sponsor Novartis
5. A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis (HZNP-HZN-825-301) – studio interventistico profit – Sponsor Amgen
6. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Psoriatic Arthritis who are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs (IM011-054) – studio interventistico profit – Sponsor BMS
7. Phase 3 Safety and Efficacy Study of Upadacitinib in Subjects with Giant Cell Arteritis: SELECT-GCA (M16-852) – studio interventistico profit – Sponsor Abbvie
8. Anifrolumab Study for Treatment Effectiveness in the Real World Multi-National Prospective, Observational, Post-Launch Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice (D3461R00043) – studio osservazionale profit – Sponsor Astra Zeneca
9. Upadacitinib treatment patterns, achievement of treatment targets and maintenance of response in moderate to severe Rheumatoid Arthritis patients in real-world practice (P20-095) – studio osservazionale profit – Sponsor Abbvie
10. Studio di sicurezza post autorizzazione (PASS): studio osservazionale di coorte su pazienti affetti da PAH trattati per la prima volta con Uptravi® (selexipag) o un'altra terapia specifica per PAH nella pratica clinica – studio osservazionale profit – Sponsor Actelion Pharmaceuticals Ltd.
11. Psoriatic Arthritis Observational Study of Persistence of Treatment (PRO-SPIRIT Study) (I1F-MC-B009) - studio osservazionale profit – Sponsor Eli Lilly.
12. Valutazione di guselkumab (Tremfya®) e terapie con inibitori di IL-17 in pazienti affetti da artrite psoriasica nella pratica clinica di routine; studio prospettico di coorte osservazionale Studio PsABIOnd (CNTO1959PSA4001) - studio osservazionale profit – Sponsor Janssen (J&J)
13. Studio osservazionale di coorte prospettico multicentrico sponsorizzato con BENLYSTA TM (Belimumab). Registro prospettico osservazionale della durata di 5 anni per la valutazione degli eventi avversi di interesse e dell'efficacia, in adulti affetti da Lupus Eritematoso Sistemico attivo, trattati con o senza BENLYSTA TM (HGS1006-C1124 SABLE) - studio osservazionale profit – Sponsor GSK
14. Real-world effectiveness and treatment patterns of UPadaciTInib in Monotherapy or Used in combination with Methotrexate in active Psoriatic Arthritis patients (Uptimum-PsA) (P22-897) - studio osservazionale profit – Sponsor Abbvie
15. A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, ulticenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy (ARGEX-113-2007) – studio interventistico profit – Sponsor Argenix
16. A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome (IM0111069) – studio interventistico profit – Sponsor BMS